EMA Recommends Stemline’s Elzonris After Initial Rejection
Executive Summary
While the European Medicine Agency now recommends that Elzonris should be approved in the EU, Stemline Therapeutics will have to submit the results of a study based on a registry of patients with blastic plasmacytoid dendritic cell neoplasm.
You may also be interested in...
European CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Phesgo & Roclanda Among New Winners At EMA
The European Medicines Agency this week recommended that five new products be granted EU marketing approval.
Phesgo & Roclanda Among New Winners At EMA
The European Medicines Agency this week recommended that five new products be granted EU marketing approval.